This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05527184
Recruitment Status : Recruiting
First Posted : September 2, 2022
Last Update Posted : February 28, 2024
Sponsor:
Information provided by (Responsible Party):
ImmunoGen, Inc.

Brief Summary:
IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.

Condition or disease Intervention/treatment Phase
Endometrial Cancer High Grade Serous Adenocarcinoma of Ovary Primary Peritoneal Carcinoma Fallopian Tube Cancer Drug: IMGN151 Phase 1

Detailed Description:
This Phase 1 study is designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IMGN151 in patients with recurrent endometrial cancer, or recurrent, high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancers. All patients will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 227 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Open-label dose escalation study with dosing every three weeks. All patients in the escalation phase will be assigned sequentially to one of up to eight doses in a 3+3 design. Once the recommended Phase 2 dose is identified, an expansion phase of the study will enroll patients into cohorts of either endometrial cancer or platinum-resistant ovarian cancer. During EscalationIMGN151 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter, at the assigned dose for each cohort during dose escalation and at the RP2D for expansion. Infusion duration will vary depending on dose and participant tolerability.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Actual Study Start Date : January 11, 2023
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : December 30, 2025


Arm Intervention/treatment
Experimental: IMGN151 Open Label
IMGN151 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter, at the assigned dose for each cohort during dose escalation, and at the RP2D for expansion. Infusion duration will vary depending on dose and participant tolerability.
Drug: IMGN151
IMGN151 is an antibody-drug conjugate (ADC).




Primary Outcome Measures :
  1. Characterize Safety (Escalation) [ Time Frame: Up to 1 year ]
    Incidence of adverse events (AE), serious adverse events (SAEs), and DLTs

  2. Define Recommended Phase 2 Dose (Escalation) [ Time Frame: Up to 1 year ]
    Definition of RP2D

  3. Determine Objective Response Rate (Expansion) [ Time Frame: Up to 3 years ]
    ORR (which includes best response of CR or PR as assessed by the investigator)


Secondary Outcome Measures :
  1. During dose escalation and expansion to characterize study drug concentration [ Time Frame: There are 9 blood draw collection time points at Cycles 1 and 3, 3 blood draw time points at Cycles 2,4,5 and 6, and collection at every 3 cycles after cycle 6 until end of study (approximately up to 2 years). Each cycle is 21 days. ]
    Study drug concentration

  2. During dose escalation and expansion to measure the concentration of anti-drug antibody [ Time Frame: There are 2 collection time points at Cycles 1 and 3, 1 collection time point at Cycles 2, 4, 5 and 6, and and collection at every 3 cycles after cycle 6 until end of study (approximately up to 2 years). Each cycle is 21 days. ]
    Anti-drug antibody

  3. During dose expansion describe the duration of response and progression-free survival [ Time Frame: From screening to end of study (approximately up to 2 years) for each patient ]
    Time to disease progression

  4. During dose escalation to describe the objective response rate and duration of response [ Time Frame: From screening to end of study (approximately up to 2 years) for each patient ]
    Time to disease progression

  5. During dose expansion measure incidence and severity of Treatment Emergent Adverse Events by CTCAE v5.0 [ Time Frame: From screening to end of study (approximately up to 2 years) for each patient ]
    Number of treatment emergent adverse events as assessed by CTCAE v5.0


Other Outcome Measures:
  1. Determine Progression Free Survival (Escalation) [ Time Frame: Up to 1 year ]
    PFS (defined as the time from first dose of IMGN151 until investigator-assessed radiological PD or death, whichever occurs first)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients ≥ 18 years of age
  2. Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  3. Dose-Escalation Phase: Patients must have a confirmed diagnosis of recurrent endometrial cancer or high-grade serous epithelial ovarian cancer (EOC), primary peritoneal, or fallopian tube cancer.
  4. Expansion Phase: Patients must have a confirmed diagnosis of recurrent endometrial cancer or platinum-resistant, high-grade serous epithelial ovarian cancer (PROC), primary peritoneal, or fallopian tube cancer.

    Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.

  5. Prior anticancer therapy

    1. For Expansion Phase: Patients must have recurrent endometrial cancer or patients with PROC must have received 1-4 prior systemic lines of therapy.
    2. Neoadjuvant ± adjuvant therapies are considered 1 line of therapy.
    3. Maintenance therapy (eg, bevacizumab or poly [ADP-ribose] polymerase [PARP] inhibitors) will be considered part of the preceding line of therapy (ie, not counted independently).
    4. Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently).
    5. Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance.
  6. Evaluable lesions

    1. Dose-Escalation Phase: Patients may have radiologically evaluable or nonevaluable disease.
    2. Expansion Phase: Patients must have at least 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the investigator).
  7. Patients must be willing to provide an archival tumor tissue block or slides or to undergo a procedure to obtain a new biopsy using a low-risk, medically routine procedure for retrospective IHC confirmation of FRα status.
  8. Patients must have completed prior therapy within the specified times below:

    1. Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) before the first dose of IMGN151
    2. Focal radiation completed at least 2 weeks before the first dose of IMGN151
  9. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia).
  10. Patients must have completed any major surgery at least 4 weeks before the first dose of IMGN151 and have recovered or stabilized from the side effects of prior surgery before the first dose of IMGN151.
  11. Patients must have adequate hematologic, liver, and kidney functions defined as follows:

    1. Absolute neutrophil count (ANC) ≥ 1.5 ×10 9/L (1500/μL) without granulocyte colony-stimulating factor (G-CSF) in the prior 10 days or long-acting white blood cell growth factors in the prior 20 days
    2. Platelet count ≥ 100 × 10 9/L (100,000/μL) without platelet transfusion in the prior 10 days
    3. Hemoglobin ≥ 9.0 g/dL without packed red blood cell transfusion in the prior 21 days
    4. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 or an estimated creatinine clearance of ≥ 60 mL/min
    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN)
    6. Serum bilirubin ≤ 1.5 × ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 × ULN)
    7. Serum albumin ≥ 2 g/dL
  12. Patients must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements.
  13. Females of childbearing potential (FOCBP) must agree to use highly effective contraceptive method(s) while on IMGN151 and for at least 3 months after the last dose.
  14. FOCBP must have a negative serum pregnancy test at Screening and a negative serum or urine pregnancy test within 72 hours before the first dose of IMGN151.

Exclusion Criteria:

  1. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumor
  2. Patients with prior wide-field radiotherapy affecting at least 20% of the bone marrow
  3. Patients with > Grade 1 peripheral neuropathy per CTCAE v5.0
  4. Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision
  5. Patients with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:

    1. Active hepatitis B or C infection (whether or not on active antiviral therapy)
    2. HIV infection in patients with CD4+ T-cell (CD4+) counts < 350 cells/µL
    3. Active cytomegalovirus infection
    4. Active COVID-19/SARS-CoV-2 infection. Although SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines and standards
    5. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks before the first dose of IMGN151 Note: Testing at Screening is not required for the above infections unless clinically indicated.
  6. Patients with a history of multiple sclerosis or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
  7. Patients with clinically significant cardiac disease including, but not limited to, any of the following:

    1. Myocardial infarction ≤ 6 months before the first dose
    2. Unstable angina pectoris
    3. Uncontrolled congestive heart failure (New York Heart Association > class II)
    4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE v5.0)
    5. Uncontrolled cardiac arrhythmias
    6. QTc interval > 470 ms
  8. Patients with a history of hemorrhagic or ischemic stroke within 6 months before enrollment
  9. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)
  10. Patients with evidence of pneumonitis on baseline imaging or patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonitis
  11. Patients requiring use of folate-containing supplements (eg, folate deficiency)
  12. Patients with prior hypersensitivity to monoclonal antibodies (mAb)
  13. Females who are pregnant or breastfeeding
  14. For Expansion Phase: Patients who received a prior FRα-targeting agent
  15. Patients with untreated or symptomatic central nervous system metastases
  16. Patients with a history of other malignancy within 3 years before enrollment Note: Patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.
  17. Prior known hypersensitivity reactions to study drugs and/or any of their excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05527184


Contacts
Layout table for location contacts
Contact: ImmunoGen, Inc. 781-895-0600 medicalinformation@immunogen.com
Contact: Eric Westin, MD 781-895-0646 Eric.Westin@immunogen.com

Locations
Layout table for location information
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90095
Contact: Gottfried Konecny, MD    310-794-4955    GKonecny@mednet.ucla.edu   
United States, Colorado
University of Colorado Anschutz Cancer Pavilion Recruiting
Aurora, Colorado, United States, 80045
Contact: Bradley R Corr, MD    303-234-1067    BRADLEY.CORR@CUANSCHUTZ.EDU   
United States, Florida
Florida Cancer Specialists Recruiting
Sarasota, Florida, United States, 34232
Contact: Judy Wang, MD    914-377-9993    jswang@flcancer.com   
United States, Oklahoma
OU Health Stephenson Cancer Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Kathleen Moore, MD    405-271-8001    Kathleen-Moore@ouhsc.edu   
United States, Tennessee
Tennessee Oncology Nashville Recruiting
Nashville, Tennessee, United States, 37203
Contact: Erika Hamilton, MD    615-320-5090    ehamilton@tnonc.com   
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Funda Meric-Bernstam, MD    713-792-2848    fmeric@mdanderson.org   
Sponsors and Collaborators
ImmunoGen, Inc.
Layout table for additonal information
Responsible Party: ImmunoGen, Inc.
ClinicalTrials.gov Identifier: NCT05527184    
Other Study ID Numbers: IMGN151-1001
First Posted: September 2, 2022    Key Record Dates
Last Update Posted: February 28, 2024
Last Verified: February 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ImmunoGen, Inc.:
Antibody Drug Conjugate
Platinum-Resistant
Recurrent
Phase 1/2
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Fallopian Tube Neoplasms
Cystadenocarcinoma, Serous
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases
Fallopian Tube Diseases
Adnexal Diseases
Cystadenocarcinoma
Neoplasms, Cystic, Mucinous, and Serous